Daré Bioscience has the sole focus of putting women’s health first – to boldly address existing therapeutic gaps and give women the novel treatment options they want and need. Daré is now the only publicly traded company focused solely on women’s health pharmaceutical product development broadly, committed to advancing through clinical development, regulatory review, and ultimately to market disruptive products for women. Daré has commercialized (Organon) product for bacterial vaginosis, and the development portfolio includes a Phase 3 hormone-free monthly vaginal contraceptive candidate, female sexual arousal disorder candidate, a monthly non-oral combination hormone therapy for menopause, two development candidates for pre-term birth, a non-hormonal treatment for vaginal atrophy for women with breast cancer, a pharmaceutical treatment for human papilloma virus and cervical dysplasia, and an implanted contraceptive that can be paused or resumed over several years, to name a few.